Brief: iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024

icad

28/02/2024 13:34

Feb 28 (Reuters) - ICAD Inc  ICAD.O :
    * ICAD HIGHLIGHTS PROMISING CLINICAL DATA DEMONSTRATING
ABILITY TO
REDUCE BREAST INTERVAL CANCER RATES AND DECREASE RECALL RATES AT
ECR 2024; SHOWCASES ADDITIONAL PLATFORM OFFERINGS
    * ICAD INC - FINDINGS REVEAL SUBSTANTIALLY LOWER RADIOLOGY
READING
WORKLOAD
    * ICAD INC - CLINICAL EVIDENCE DEMONSTRATES PROFOUND
DETECTION'S
AI MAY HELP REDUCE BREAST INTERVAL CANCER (IC) RATES AND
DECREASE RECALL RATES

Source text for Eikon:  ID:nGNX9J7cBG 
Further company coverage:  ICAD.O 

 ((Reuters.Briefs@thomsonreuters.com;))